RxDoctor Payments Data

Mehran Jabbarzadeh, MD

Clinical Cardiac Electrophysiology · Kenosha, WINPI 1164483145

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Boston Scientific at 42.8% of the total. Reporting peaked in 2019 at $12,110 and has fallen 97.1% since, to $349 in 2025.

$35,468in general payments, 2019–2025

Across 150 payments — averaging $236.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$15K
  • Medtronic$8K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Pfizer$5K
  • Abbott$370
  • Johnson & Johnson$166
  • plus $420 from 8 others

What the payments were for

  • Consulting fees$18,42552%
  • Speaking & faculty fees$10,72530%
  • Travel & lodging$1,2854%
  • Food & beverage$4,97314%
  • Education$100%
  • Other$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,468 in reported general payments places this provider in the 75th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

See all clinical cardiac electrophysiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$278,005
Medicare patients
1,006
Services billed
3,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban697$905,783
XareltoRivaroxaban186$255,217
MultaqDronedarone Hcl20$35,790
Dofetilide152$20,134
CorlanorIvabradine Hcl12$17,595
Flecainide Acetate209$8,989
Dabigatran EtexilateDabigatran Etexilate Mesylate21$6,557
SotalolSotalol Hcl243$5,919
Bisoprolol Fumarate161$5,239
Metoprolol Succinate270$4,116
Amiodarone Hcl175$2,386
Nebivolol Hcl44$2,065
Propranolol Hcl ErPropranolol Hcl48$1,696
Metoprolol Tartrate147$1,405
Carvedilol140$1,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$5,216$905,783697 claims
Johnson & JohnsonXarelto$166$255,217186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 78 clinical cardiac electrophysiology providers in Wisconsin.

Other clinical cardiac electrophysiology in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →